financetom
Business
financetom
/
Business
/
JPMorgan profit jumps on higher investment banking fees, accounting gain
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan profit jumps on higher investment banking fees, accounting gain
Jul 12, 2024 4:34 AM

(Reuters) - JPMorgan Chase's ( JPM ) profit rose in the second quarter, buoyed by rising investment banking fees and an $8 billion accounting gain from a share exchange deal with Visa.

Investment banks have benefited from a resurgence in capital-raising activity both in debt and equities markets.

Wall Street banks are also seeing an uptick in fee income from advising on M&A deals as companies become more confident on the U.S. economy's ability to avoid a major downturn.

"While market valuations and credit spreads seem to reflect a rather benign economic outlook, we continue to be vigilant about potential tail risks," CEO Jamie Dimon said adding that the risks included a changing geopolitical situation, which remains the most dangerous since World War II.

The largest U.S. bank's profit was $18.15 billion, or $6.12 per share, for the three months ended June 30, compared with $14.47 billion, or $4.75 per share, a year earlier, it said on Friday.

The bank benefited from a plan to exchange some of its shares in Visa, the world's largest payment network.

Investment banking fees grew 50%, compared with a low base, but was higher than an earlier company prediction of 25% to 30%.

JPMorgan ( JPM ) also extended its gains from lending, with net interest income (NII) - the difference between what it earns on loans and pays out on deposits - growing 4% to $22.9 billion versus a year earlier.

Lending has remained healthy even as banks compete for deposits and face pressure to shell out more to depositors to store their money.

(Reporting by Niket Nishant in Bengaluru and Nupur Anand in New York, editing by Lananh Nguyen and Anil D'Silva)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ConocoPhillips, Marathon Oil get second US FTC request over $22.5 bln deal
ConocoPhillips, Marathon Oil get second US FTC request over $22.5 bln deal
Jul 12, 2024
July 12 (Reuters) - Top U.S. independent oil producer ConocoPhillips ( COP ) said on Friday it received a second request from the U.S. Federal Trade Commission for information on its proposed acquisition of rival Marathon Oil ( MRO ). ConocoPhillips ( COP ) said both companies received the requests on July 11 and are working with the FTC to...
ConocoPhillips, Marathon Oil get second US FTC request over $22.5 billion deal
ConocoPhillips, Marathon Oil get second US FTC request over $22.5 billion deal
Jul 12, 2024
(Reuters) - Top U.S. independent oil producer ConocoPhillips ( COP ) said on Friday it received a second request from the U.S. Federal Trade Commission for information on its proposed acquisition of rival Marathon Oil ( MRO ). ConocoPhillips ( COP ) said both companies received the requests on July 11 and are working with the FTC to review the...
JPMorgan profit jumps on higher investment banking fees, accounting gain
JPMorgan profit jumps on higher investment banking fees, accounting gain
Jul 12, 2024
(Reuters) - JPMorgan Chase's ( JPM ) profit rose in the second quarter, buoyed by rising investment banking fees and an $8 billion accounting gain from a share exchange deal with Visa. Investment banks have benefited from a resurgence in capital-raising activity both in debt and equities markets. Wall Street banks are also seeing an uptick in fee income from...
Novo Nordisk's Ozempic Reduces Dementia and Cognitive Risks, Oxford Study Says
Novo Nordisk's Ozempic Reduces Dementia and Cognitive Risks, Oxford Study Says
Jul 12, 2024
07:03 AM EDT, 07/12/2024 (MT Newswires) -- Novo Nordisk's ( NVO ) Ozempic may reduce the risk of dementia and other neurological issues compared to older antidiabetic medications like sitagliptin and glipizide, according to a study by the University of Oxford and published by The Lancet's eClinicalMedicine journal on Wednesday. After a year on Ozempic, patients showed a lower risk...
Copyright 2023-2026 - www.financetom.com All Rights Reserved